tiprankstipranks
AstraZeneca PLC (MX:AZN1N)
:AZN1N
Mexico Market
AZN1N
AstraZeneca
RESEARCH TOOLSreports

AstraZeneca (AZN1N) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

AZN1N Analyst Ratings

Strong Buy
14Ratings
Strong Buy
12 Buy
1 Hold
1 Sell
Based on 14 analysts giving stock ratings to
AstraZeneca
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AZN1N Stock 12 Month Forecast

Average Price Target

$3,725.25
▲(25.67% Upside)
Based on 14 Wall Street analysts offering 12 month price targets for AstraZeneca in the last 3 months. The average price target is $3,725.25 with a high forecast of $4,675.85 and a low forecast of $2,662.00. The average price target represents a 25.67% change from the last price of $2,964.41.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2660":"$2,660","3164":"$3,164","3668":"$3,668","4172":"$4,172","4676":"$4,676"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":4675.852974,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$4.68K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3725.2505212,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.73K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2661.995505,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.66K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2660,3164,3668,4172,4676],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2942.517,3075.8505364615385,3209.1840729230767,3342.5176093846153,3475.851145846154,3609.184682307692,3742.5182187692308,3875.8517552307694,4009.185291692308,4142.518828153847,4275.852364615384,4409.185901076923,4542.519437538462,{"y":4675.852974,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2942.517,3002.7272708615383,3062.9375417230767,3123.147812584615,3183.3580834461536,3243.568354307692,3303.7786251692305,3363.988896030769,3424.199166892308,3484.4094377538463,3544.6197086153848,3604.829979476923,3665.0402503384616,{"y":3725.2505212,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2942.517,2920.938423461538,2899.359846923077,2877.7812703846153,2856.2026938461536,2834.6241173076924,2813.0455407692307,2791.466964230769,2769.8883876923073,2748.309811153846,2726.7312346153844,2705.1526580769228,2683.5740815384615,{"y":2661.995505,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2725.298,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2930.734,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2710.424,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2710.424,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3313.734,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3232.841,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3176.982,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3498.903,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3259.439,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3288.228,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3145.175,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3242.183,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2942.517,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$4,676Average Price Target$3,725Lowest Price Target$2,662
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on MX:AZN1N
Sachin Jain
Bank of America Securities
Bank of America Securities
$3,819.38
Buy
28.84%
Upside
Reiterated
08/07/26
AstraZeneca: Buy Rating Reiterated on Attractive Valuation, Robust Pipeline, and Unchanged $16,500 Price Target
Jefferies Analyst forecast on MX:AZN1N
Michael Leuchten
Jefferies
Jefferies
$4,050.83
Buy
36.65%
Upside
Reiterated
08/07/26
Jefferies Reaffirms Their Buy Rating on AstraZeneca (AZN)
UBS Analyst forecast on MX:AZN1N
Matthew Weston
UBS
UBS
$4,074.01
Buy
37.43%
Upside
Reiterated
08/04/26
AstraZeneca (AZN) Receives a Buy from UBS
Deutsche Bank Analyst forecast on MX:AZN1N
Emmanuel Papadakis
Deutsche Bank
Deutsche Bank
$2,661.98
Sell
-10.20%
Downside
Reiterated
08/04/26
AstraZeneca (AZN) Gets a Sell from Deutsche Bank
Citi Analyst forecast on MX:AZN1N
Graham Parry
Citi
Citi
―
Buy
―
Reiterated
08/04/26
AstraZeneca: Buy Rating Reaffirmed as Robust Pipeline and Strategic Optionality Drive Price Target Raise to $178
J.P. Morgan Analyst forecast on MX:AZN1N
Richard Vosser
J.P. Morgan
J.P. Morgan
$3,703.62
Buy
24.94%
Upside
Reiterated
08/03/26
J.P. Morgan Sticks to Its Buy Rating for AstraZeneca (AZN)
Bernstein Analyst forecast on MX:AZN1N
Justin Smith
Bernstein
Bernstein
$4,282.31→$4,675.82
Buy
57.73%
Upside
Reiterated
07/29/26
Bernstein Sticks to Their Buy Rating for AstraZeneca (AZN)
DZ BANK AG Analyst forecast on MX:AZN1N
Elmar Kraus
DZ BANK AG
DZ BANK AG
―
Buy
―
Reiterated
07/28/26
DZ BANK AG Sticks to Their Buy Rating for AstraZeneca (AZN)
Barclays Analyst forecast on MX:AZN1N
James Gordon CFA
Barclays
Barclays
$3,819.36
Buy
28.84%
Upside
Reiterated
07/28/26
AstraZeneca (AZN) Gets a Buy from Barclays
Goldman Sachs Analyst forecast on MX:AZN1N
Rajan Sharma
Goldman Sachs
Goldman Sachs
$3,703.65→$3,719.85
Buy
25.48%
Upside
Reiterated
07/28/26
Goldman Sachs Reaffirms Their Buy Rating on AstraZeneca (AZN)
Berenberg Bank Analyst forecast on MX:AZN1N
Luisa Hector
Berenberg Bank
Berenberg Bank
$3,703.62
Buy
24.94%
Upside
Reiterated
07/27/26
AstraZeneca (AZN) Gets a Buy from Berenberg Bank
Morgan Stanley Analyst forecast on MX:AZN1N
Sarita Kapila
Morgan Stanley
Morgan Stanley
$3,819.38→$3,541.61
Buy
19.47%
Upside
Reiterated
07/16/26
Morgan Stanley Remains a Buy on AstraZeneca (AZN)
HSBC Analyst forecast on MX:AZN1N
Rajesh Kumar
HSBC
HSBC
$3,182.82
Hold
7.37%
Upside
Downgraded
07/13/26
AstraZeneca (AZN) was downgraded to a Hold Rating at HSBC
Guggenheim Analyst forecast on MX:AZN1N
Seamus Fernandez
Guggenheim
Guggenheim
$3,819.36→$3,749.91
Buy
26.50%
Upside
Reiterated
07/09/26
Guggenheim Keeps Their Buy Rating on AstraZeneca (AZN)
TD Cowen Analyst forecast on MX:AZN1N
Steve Scala
TD Cowen
TD Cowen
―
Buy
―
Reiterated
04/30/26
TD Cowen Keeps Their Buy Rating on AstraZeneca (AZN)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on MX:AZN1N
Sachin Jain
Bank of America Securities
Bank of America Securities
$3,819.38
Buy
28.84%
Upside
Reiterated
08/07/26
AstraZeneca: Buy Rating Reiterated on Attractive Valuation, Robust Pipeline, and Unchanged $16,500 Price Target
Jefferies Analyst forecast on MX:AZN1N
Michael Leuchten
Jefferies
Jefferies
$4,050.83
Buy
36.65%
Upside
Reiterated
08/07/26
Jefferies Reaffirms Their Buy Rating on AstraZeneca (AZN)
UBS Analyst forecast on MX:AZN1N
Matthew Weston
UBS
UBS
$4,074.01
Buy
37.43%
Upside
Reiterated
08/04/26
AstraZeneca (AZN) Receives a Buy from UBS
Deutsche Bank Analyst forecast on MX:AZN1N
Emmanuel Papadakis
Deutsche Bank
Deutsche Bank
$2,661.98
Sell
-10.20%
Downside
Reiterated
08/04/26
AstraZeneca (AZN) Gets a Sell from Deutsche Bank
Citi Analyst forecast on MX:AZN1N
Graham Parry
Citi
Citi
―
Buy
―
Reiterated
08/04/26
AstraZeneca: Buy Rating Reaffirmed as Robust Pipeline and Strategic Optionality Drive Price Target Raise to $178
J.P. Morgan Analyst forecast on MX:AZN1N
Richard Vosser
J.P. Morgan
J.P. Morgan
$3,703.62
Buy
24.94%
Upside
Reiterated
08/03/26
J.P. Morgan Sticks to Its Buy Rating for AstraZeneca (AZN)
Bernstein Analyst forecast on MX:AZN1N
Justin Smith
Bernstein
Bernstein
$4,282.31→$4,675.82
Buy
57.73%
Upside
Reiterated
07/29/26
Bernstein Sticks to Their Buy Rating for AstraZeneca (AZN)
DZ BANK AG Analyst forecast on MX:AZN1N
Elmar Kraus
DZ BANK AG
DZ BANK AG
―
Buy
―
Reiterated
07/28/26
DZ BANK AG Sticks to Their Buy Rating for AstraZeneca (AZN)
Barclays Analyst forecast on MX:AZN1N
James Gordon CFA
Barclays
Barclays
$3,819.36
Buy
28.84%
Upside
Reiterated
07/28/26
AstraZeneca (AZN) Gets a Buy from Barclays
Goldman Sachs Analyst forecast on MX:AZN1N
Rajan Sharma
Goldman Sachs
Goldman Sachs
$3,703.65→$3,719.85
Buy
25.48%
Upside
Reiterated
07/28/26
Goldman Sachs Reaffirms Their Buy Rating on AstraZeneca (AZN)
Berenberg Bank Analyst forecast on MX:AZN1N
Luisa Hector
Berenberg Bank
Berenberg Bank
$3,703.62
Buy
24.94%
Upside
Reiterated
07/27/26
AstraZeneca (AZN) Gets a Buy from Berenberg Bank
Morgan Stanley Analyst forecast on MX:AZN1N
Sarita Kapila
Morgan Stanley
Morgan Stanley
$3,819.38→$3,541.61
Buy
19.47%
Upside
Reiterated
07/16/26
Morgan Stanley Remains a Buy on AstraZeneca (AZN)
HSBC Analyst forecast on MX:AZN1N
Rajesh Kumar
HSBC
HSBC
$3,182.82
Hold
7.37%
Upside
Downgraded
07/13/26
AstraZeneca (AZN) was downgraded to a Hold Rating at HSBC
Guggenheim Analyst forecast on MX:AZN1N
Seamus Fernandez
Guggenheim
Guggenheim
$3,819.36→$3,749.91
Buy
26.50%
Upside
Reiterated
07/09/26
Guggenheim Keeps Their Buy Rating on AstraZeneca (AZN)
TD Cowen Analyst forecast on MX:AZN1N
Steve Scala
TD Cowen
TD Cowen
―
Buy
―
Reiterated
04/30/26
TD Cowen Keeps Their Buy Rating on AstraZeneca (AZN)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
ZURAZura Bio
TNYATenaya Therapeutics
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AstraZeneca

3 Months
Emmanuel PapadakisDeutsche Bank
Success Rate
39/61 ratings generated profit
64%
Average Return
+4.89%
Copying Emmanuel Papadakis's trades and holding each position for 3 Months would result in 63.93% of your transactions generating a profit, with an average return of +4.89% per trade.
1 Year
Matthew WestonUBS
Success Rate
33/41 ratings generated profit
80%
Average Return
+13.52%
Copying Matthew Weston's trades and holding each position for 1 Year would result in 80.49% of your transactions generating a profit, with an average return of +13.52% per trade.
2 Years
Emmanuel PapadakisDeutsche Bank
Success Rate
51/61 ratings generated profit
84%
Average Return
+20.74%
Copying Emmanuel Papadakis's trades and holding each position for 2 Years would result in 83.61% of your transactions generating a profit, with an average return of +20.74% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AZN1N Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
0
0
0
1
2
Buy
46
45
43
56
53
Hold
3
1
1
1
1
Sell
7
7
8
10
8
Strong Sell
0
0
0
0
0
total
56
53
52
68
64
In the current month, AZN1N has received 55 Buy Ratings, 1 Hold Ratings, and 8 Sell Ratings. AZN1N average Analyst price target in the past 3 months is 3,725.25.
Each month's total comprises the sum of three months' worth of ratings.

AZN1N Financial Forecast

AZN1N Earnings Forecast

Next quarter’s earnings estimate for AZN1N is $45.26 with a range of $42.32 to $50.92. The previous quarter’s EPS was $45.25. AZN1N beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 37.50% of the time in the same period. In the last calendar year AZN1N has Performed in-line its overall industry.
Next quarter’s earnings estimate for AZN1N is $45.26 with a range of $42.32 to $50.92. The previous quarter’s EPS was $45.25. AZN1N beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 37.50% of the time in the same period. In the last calendar year AZN1N has Performed in-line its overall industry.

AZN1N Sales Forecast

Next quarter’s sales forecast for AZN1N is $276.16B with a range of $272.36B to $280.76B. The previous quarter’s sales results were $265.30B. AZN1N beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.91% of the time in the same period. In the last calendar year AZN1N has Performed in-line its overall industry.
Next quarter’s sales forecast for AZN1N is $276.16B with a range of $272.36B to $280.76B. The previous quarter’s sales results were $265.30B. AZN1N beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.91% of the time in the same period. In the last calendar year AZN1N has Performed in-line its overall industry.

AZN1N Stock Forecast FAQ

What is MX:AZN1N’s average 12-month price target, according to analysts?
Based on analyst ratings, AstraZeneca PLC’s 12-month average price target is 3,725.25.
    What is MX:AZN1N’s upside potential, based on the analysts’ average price target?
    AstraZeneca PLC has 25.67% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is AstraZeneca PLC a Buy, Sell or Hold?
          AstraZeneca PLC has a consensus rating of Strong Buy, which is based on 12 buy ratings, 1 hold ratings and 1 sell ratings.
            What is AstraZeneca PLC’s share price target?
            The average share price target for AstraZeneca PLC is 3,725.25. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $4,675.85 ,and the lowest forecast is $2,662.00. The average share price target represents 25.67% Increase from the current price of $2,964.41.
              What do analysts say about AstraZeneca PLC?
              AstraZeneca PLC’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.
                How can I buy shares of AstraZeneca PLC?
                To buy shares of MX:AZN1N, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.